<DOC>
	<DOC>NCT01712412</DOC>
	<brief_summary>The objectives of this study are to determine the safety and efficacy of IW-9179 administered to patients with functional dyspepsia (FD).</brief_summary>
	<brief_title>Phase 2a Study of IW-9179 to Treat Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Patient meets ROME III criteria for functional dyspepsia (FD) Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening Period or within 2 years of the Screening Visit Patients who EITHER: 1. Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening Visit, OR 2. Have used a PPI at a stable dose for at least 4 weeks prior to the Screening Visit; Patient meets symptom severity criteria in the Pretreatment Period Patient is fluent and literate in Dutch, French, or English Patient meets criteria for gastroesophageal reflux disease (GERD, stable regimen of PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis Patient has a history of inflammatory bowel disease, chronic pancreatitis, small intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic kidney disease, interstitial cystitis, or scleroderma Any significant neurological disease or a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable; complete remission of other cancers for 5 years or longer is also acceptable) History of active alcoholism or drug addiction within 12 months prior to the Screening Visit Hospitalized for a psychiatric condition or has made a suicide attempt during the two years before the Screening Visit Any organic or structural disease that can cause abdominal pain or discomfort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>